Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Pembrolizumab + EDP1503 for Advanced Melanoma
Recruiting2 awardsPhase 2
Chicago, Illinois
This trial aims to see if taking EDP1503 by mouth will improve how well standard immunotherapy (pembrolizumab) works in people with advanced melanoma. Participants will first take
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service